share_log

Chardan Capital Upgrades Outlook Therapeutics to Buy, Announces $3 Price Target

Benzinga ·  Feb 15 20:29

Chardan Capital analyst Daniil Gataulin upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $3 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment